Cited by 163Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Indicators of amyloid burden in a population-based study of cognitively normal elderly

Open access

Mielke, Michelle M., Wiste, Heather J., Weigand, Stephen D., Knopman, David S., Lowe, Val J., Roberts, Rosebud O., Geda, Yonas E., Swenson-Dravis, Dana M., Boeve, Bradley F., Senjem, Matthew L., Vemuri, Prashanthi, Petersen, Ronald C., Jack, Clifford R.·2012·Neurology

DOI 10.1212/wnl.0b013e31826e2696PMC PMC3475629

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs. METHODS: A total of 483 cognitively normal (CN) individuals, aged 70-92 years, from the population-based Mayo Clinic Study of Aging, underwent Pittsburgh compound B (PiB)-PET imaging. Logistic regression determined whether age, sex, APOE genotype, family history, or cognitive performance was associated with odds of a PiB retention ratio >1.4 and >1.5. Area under the receiver operating characteristic curve (AUROC) evaluated the discrimination between PiB-positive and -negative subjects. For each characteristic, we determined the number needed to screen in each age group (70-79 and 80-89) to identify 100 participants with PiB >1.4 or >1.5. RESULTS: A total of 211 (44%) individuals had PiB >1.4 and 151 (31%) >1.5. In univariate and multivariate models, discrimination was modest (AUROC ∼0.6-0.7). Multivariately, age and APOE best predicted odds of PiB >1.4 and >1.5. Subjective memory complaints were similar to cognitive test performance in predicting PiB >1.5. Indicators of PiB positivity varied with age. Screening APOE ε4 carriers alone reduced the number needed to screen to enroll 100 subjects with PIB >1.5 by 48% in persons aged 70-79 and 33% in those aged 80-89. CONCLUSIONS: Age and APOE genotype are useful predictors of the likelihood of significant amyloid accumulation, but discrimination is modest. Nonetheless, these results suggest that inexpensive and noninvasive measures could significantly reduce the number of CN individuals needed to screen to enroll a given number of amyloid-positive subjects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e31826e2696

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citation
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citation
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Self-citation
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia
Sperling, R. A., LaViolette, P. S., O'Keefe, K., O'Brien, J., Rentz, D. M., Pihlajamaki, M., Marshall, G., Hyman, B. T., Selkoe, D. J., Hedden, T., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.07.003 · Cited by 1,027
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986

Show all 34 references

Sorted by citations

Items 101–163 of 163

Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults
Nadkarni, N. K., López, O. L., Perera, S., Studenski, S. A., Snitz, B. E., Erickson, K. I., Mathis, C. A., Nebes, R. D., Redfern, M. S., & Klunk, W. E. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw211 · Cited by 22
Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting
Jiménez-Bonilla, J. F., Banzo, I., de Arcocha-Torres, M., Quirce, R., Martínez‐Rodríguez, I., Sánchez‐Juan, P., & CARRIL, J. M. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000934 · Cited by 21
Detecting Amyloid Positivity in Elderly With Increased Risk of Cognitive Decline
Pekkala, T., Hall, A., Ngandu, T., van Gils, M., Helisalmi, S., Hänninen, T., Kemppainen, N. M., Liu, Y., Lötjönen, J. M. P., Paajanen, T. I., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00228 · Cited by 21
An approach to classifying subjective cognitive decline in community‐dwelling elders
Rabin, L. A., Wang, C., Mogle, J. A., Lipton, R. B., Derby, C. A., & Katz, M. J. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12103 · Cited by 19
Linking self-perceived cognitive functioning questionnaires using item response theory: The subjective cognitive decline initiative.
Rabin, L. A., Initiative, T. A. D. N., Sikkes, S. A. M., Tommet, D., Jones, R. N., Crane, P. K., Elbulok-Charcape, M. M., Dubbelman, M. A., Koscik, R. L., Amariglio, R. E., et al. (2023) · Neuropsychology · doi:10.1037/neu0000888 · Cited by 23
Self-citation
Glucose 6 phosphate dehydrogenase overexpression rescues the loss of cognition in the double transgenic APP/PS1 mouse model of Alzheimer’s disease
Correas, Á. G., González, G. O., Roca, M., Blanco-Gandía, M. C., Nascimento, C. M. C., Lahoz, A., Rodríguez‐Arias, M., Miñarro, J., Gómez‐Cabrera, M. C., & Viña, J. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103242 · Cited by 18
Sex Differences in in vivo Alzheimer’s Disease Neuropathology in Late Middle-Aged Hispanics
Luchsinger, J. A., Palta, P., Rippon, B., Soto, L., Ceballos, F., Pardo, M., Laing, K. K., Igwe, K. C., Johnson, A. S., Tomljanovic, Z., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191183 · Cited by 18
Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease
Buckley, R. F. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01026-5 · Cited by 18
Depressive Symptoms in Clinical and Incipient Alzheimer’s Disease
Hsiao, J. J., & Teng, E. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.10 · Cited by 18
The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale – Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment
Ba, M., Ng, K. P., Gao, X., Kong, M., Guan, L., Yu, L., & Initiative, T. A. D. N. (2018) · European Journal of Neurology · doi:10.1111/ene.13881 · Cited by 16
Risk factors for amyloid positivity in older people reporting significant memory concern
Zhang, J., Zhou, W., Cassidy, R. M., Su, H., Su, Y., & Zhang, X. (2017) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2017.09.015 · Cited by 17
Predicting positivity for a new era of Alzheimer disease prevention trials
Burns, J. M., & Klunk, W. E. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e26db · Cited by 13
Quantitative informant‐ and self‐reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4
Sánchez‐Benavides, G., Salvadó, G., Arenaza‐Urquijo, E. M., Grau‐Rivera, O., Suárez‐Calvet, M., Milà‐Alomà, M., Gónzalez‐de‐Echávarri, J. M., Minguillón, C., Crous‐Bou, M., Niñerola‐Baizán, A., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12127 · Cited by 12
Impact of sex and APOE ε4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults
Petersen, K. K., Grober, E. H., Lipton, R. B., Sperling, R. A., Buckley, R. F., Aisen, P. S. S., & Ezzati, A. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12271 · Cited by 10
Amyloid imaging in Alzheimer's disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0507-3 · Cited by 12
APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults
Hollands, S., Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Harrington, K., Porter, T., Snyder, P. J., Ames, D. J., Fowler, C. J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161019 · Cited by 11
Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment
Viswanathan, A., Greenberg, S. M., & Scheltens, P. (2015) · Stroke · doi:10.1161/strokeaha.115.009010 · Cited by 10
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry
Lee, A. K. W., Collier, M. K., Thompson, L. I., Popescu, D. L., Arthur, E., Correia, S., Salloway, S., & Alber, J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.12 · Cited by 9
A Potential Association Between Retinal Changes, Subjective Memory Impairment, and Anxiety in Older Adults at Risk for Alzheimer’s Disease: A 27-Month Pilot Study
Cheng, D. L., Thompson, L. I., & Snyder, P. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00288 · Cited by 11
Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment
Kemppainen, N. M., Joutsa, J., Johansson, J. J., Scheinin, N. M., Någren, K., Rokka, J., Parkkola, R. K., & Rinne, J. O. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150190 · Cited by 9
Predicting amyloid status using self‐report information from an online research and recruitment registry: The Brain Health Registry
Ashford, M. T., Neuhaus, J. M., Jin, C., Camacho, M. R., Fockler, J., Truran, D., Mackin, R. S., Rabinovici, G. D., Weiner, M. W., & Nosheny, R. L. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12102 · Cited by 8
Brain structural indicators of β-amyloid neuropathology
Jang, I., Li, B., Rashid, B., Jacoby, J. R., Huang, S. Y., Dickerson, B. C., & Salat, D. H. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.01.005 · Cited by 8
The Aging Patterns of Brain Structure, Function, and Energy Metabolism
Dang, M., Sang, F., Long, S., & Chen, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1627-6_7 · Cited by 8
Molecular Imaging of Extrapyramidal Movement Disorders
Frey, K. A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.007 · Cited by 8
Associations Between Cognitive Complaints, Memory Performance, Mood, and Amyloid-β Accumulation in Healthy Amyloid Negative Late-Midlife Individuals
Narbutas, J., Egroo, M. V., Chylinski, D., Bahri, M. A., Koshmanova, E., Talwar, P., Besson, G., Muto, V., Schmidt, C., Luxen, A., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210332 · Cited by 8
A guide for researchers seeking training in retrospective data harmonization for population neuroscience studies of Alzheimer's disease and related dementias
Shaaban, C. E., Tudorascu, D., Glymour, M. M., Cohen, A. D., Thurston, R. C., Snyder, H. M., Hohman, T. J., Mukherjee, S., Yu, L., & Snitz, B. E. (2022) · Frontiers in Neuroimaging · doi:10.3389/fnimg.2022.978350 · Cited by 9
Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry
Albright, J., Ashford, M. T., Jin, C., Neuhaus, J. M., Rabinovici, G. D., Truran, D., Maruff, P. T., Mackin, R. S., Nosheny, R. L., & Weiner, M. W. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12207 · Cited by 6
Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration
Kara, F., Lohse, C. M., Castillo, A. M., Tosakulwong, N., Lesnick, T. G., Jack, C. R., Petersen, R. C., Olson, J. E., Couch, F. J., Ruddy, K. J., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5175 · Cited by 6
Self-citation
Predicting amyloid‐beta pathology in the general population
Ho, P. T. N., van Arendonk, J., Steketee, R. M. E., van Rooij, F. J. A., Roshchupkin, G. V., Ikram, M. A., Vernooij, M. W., & Neitzel, J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13161 · Cited by 7
A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation
Prins, S., Zhuparris, A., Hart, E. P., Doll, R. J., & Groeneveld, G. J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00874-9 · Cited by 8
Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA
Moretti, D. V., Kuhn, E., Dubbelman, M. A., Sikkes, S. A. M., Castilhos, R. M., Chapman, S., Gifford, K. A., Butterbrod, E., & Nosheny, R. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70847 · Cited by 6
Measurement of Subjective Cognitive Decline (SCD) Using Korean-Everyday Cognition (K-ECog) as a Screening Tool: a Feasibility Study
Song, M., Lee, S. H., Kim, S. Y., & Kang, Y. (2021) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2021.20.4.80 · Cited by 5
Statistical Parametric Mapping in Amyloid Positron Emission Tomography
Smith, N. M., Ford, J. N., Haghdel, A., Glodzik, L., Li, Y., D’Angelo, D., RoyChoudhury, A., Wang, X., Blennow, K., de Leon, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.849932 · Cited by 5
Changes in self‐ and study partner–perceived cognitive functioning in relation to amyloid status and future clinical progression: Findings from the SCIENCe project
Dubbelman, M. A., Sikkes, S. A. M., Ebenau, J. L., van Leeuwenstijn, M. S. S. A., Kroeze, L. A., Trieu, C., van Berckel, B. N. M., Teunissen, C. E., van Harten, A. C., & van der Flier, W. M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12931 · Cited by 5
Prediction of Amyloidosis from Neuropsychological and MRI Data for Cost Effective Inclusion of Pre-symptomatic Subjects in Clinical Trials
for the ADNI, A. T. I. S. G., Ansart, M., Epelbaum, S., Gagliardi, G. P., Colliot, O., Dormont, D., Dubois, B., Hampel, H. J., & Durrleman, S. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-67558-9_41 · Cited by 5
Family History of Dementia in Old-Age Participants with Subjective Memory Complaints Predicts Own Risk for Dementia in a Longitudinal Multi-Center Cohort Study
Heser, K., Kleineidam, L., Wagner, M., Luppa, M., Löbner, M., Wiese, B., Oey, A., König, H., Brettschneider, C., van der Leeden, C., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230410 · Cited by 6
Neuropathological and sociodemographic factors associated with the cortical amyloid load in aging and Alzheimer’s disease
da Silva, S. P., Castro, C. C. M., Rabelo, L. N., Engelberth, R. C. G. J., Fernández‐Calvo, B., & Fiuza, F. P. (2023) · GeroScience · doi:10.1007/s11357-023-00982-4 · Cited by 6
Predicting amyloid beta accumulation in cognitively unimpaired older adults: Cognitive assessments provide no additional utility beyond demographic and genetic factors
Liu, S., Maruff, P. T., Saint‐Jalmes, M., Bourgeat, P., Masters, C. L., Goudey, B., & for the Alzheimer's Disease Neuroimaging Initiative, A. T. A. I. B. A. L. F. S. O. A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70036 · Cited by 7
Journal Club: Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology
Brosch, J. R., & Matthews, B. R. (2014) · Neurology · doi:10.1212/wnl.0000000000000164 · Cited by 4
The Aging Mind in Transition
Park, D. C., & Farrell, M. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411469-2.00005-4 · Cited by 4
PET Amyloid and Tau Status Are Differently Affected by Patient Features
Tan, M., Initiative, A. D. N., Yang, Y., Wang, H.-F., Xu, W., Tan, C., Zuo, C., Dong, Q., Tan, L., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200124 · Cited by 4
Comparison of amyloid PET acquired through standardized and unstandardized protocols
Cody, K. A., Sokolowski, A., Guerra, L. M., Insel, P. S., Jagust, W., Harrison, T. M., & Mormino, E. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70697 · Cited by 3
Subjective cognitive decline and cerebral-cognitive reserve in late age
Sidenkova, A. P., Calabrese, V., Tomasello, M., & Fritsch, T. (2023) · Translational Medicine of Aging · doi:10.1016/j.tma.2023.11.001 · Cited by 4
Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females
Robinson, C. G., Binette, A. P., Horie, K., Sato, C., Schindler, S. E., Bateman, R. J., Benzinger, T. L. S., Janelidze, S., Singleton, E. H., Stomrud, E., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07934-y · Cited by 2
Sex-Specific Entorhinal Cortex Functional Connectivity in Cognitively Normal Older Adults with Amyloid-β Pathology
Gong, L., Liu, D., Zhang, B., Yu, S., & Xi, C. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04243-z · Cited by 2
Influence of age and sex on presymptomatic phases of neurodegenerative diseases: Focus on multiple sclerosis and Alzheimer's disease
Zeydan, B., & Kantarci, K. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.06.015 · Cited by 2
A Simple Tool to Reach Populations at Risk for Developing Dementia and Alzheimer’s Disease
Bregman, N., Regev, K., Moore, O., Giladi, N., & Ash, E. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142724 · Cited by 2
P300-tracking of changes in information processing / working memory in preclinical alzheimer’s and mild cognitive impairments (MCI)
Miranda, P., Cox, C. D., Alexander, M., Lakey, J. R. T., & Danev, S. (2020) · Journal of Systems and Integrative Neuroscience · doi:10.15761/jsin.1000233 · Cited by 2
Could Temperamental Features Modulate Participation in Clinical Trials?
Cintoli, S., Elefante, C., Radicchi, C., Brancati, G. E., Bacciardi, S., Bonaccorsi, J., Siciliano, G., Maremmani, I., Perugi, G., & Tognoni, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031121 · Cited by 2
Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer’s Disease
Seo, Y., Jang, H., & Lee, H. (2022) · Life · doi:10.3390/life12020275 · Cited by 1
Risk scores of incident mild cognitive impairment in a Beijing community-based older cohort
Li, X., Xia, J., Li, Y., Xu, K., Chen, K., Zhang, J., Li, H., & Zhang, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.976126 · Cited by 1
PET and CSF amyloid-β status are differently predicted by patient features: Information from discordant casesPreprint
Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., Barkhof, F., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/673467
Sex differences in neuroimaging biomarkers in healthy subjects and dementia
Massa, F., Arnaldi, D., Balma, M., Bauckneht, M., Chincarini, A., Ferraro, P. M., Grazzini, M., Lapucci, C., Meli, R., Morbelli, S. D., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819344-0.00009-0
Amyloid imaging in alzheimer’s disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0485-5
Novel perspectives from existing data on early Alzheimer’s disease pathology and dementia care use
Janssen, O. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220617oj
Health Literacy Mediates the Relationships of Cognitive and Physical Functions with Health-related Quality of Life in Older Adults: Cross-sectional Observational Study (Preprint)Preprint
Chow, B. C., Duong, T. V., Jiao, J., HASSEL, H., Kwok, T. C. Y., Nguyen, M. H., & Liu, H. (2022) · doi:10.2196/preprints.41380
Субъективное когнитивное снижение (терминологические и диагностические границы)
Sidenkova, A. P., Тимофеевна, Б. Л., Babushkina, E. I., & Соколова, И. В. (2023) · Сибирский вестник психиатрии и наркологии · doi:10.26617/1810-3111-2023-3(120)-70-79
Exploring the Relationship Between Amyloid Burden and Depression in Pre-clinical Alzheimer’s Disease
Benyahia, S. A., Kahlon, S., Rijnhart, J. J. M., & Bishnoi, R. J. (2024) · Cureus · doi:10.7759/cureus.69716
Diagnostic utility of tectal plate measures in clinical variants of progressive supranuclear palsy
Singh, N. A., Blakey, M., Satoh, R., Ali, F., Pham, N. T. T., Amrami, A., Stephens, Y. C., Dickson, D. W., Josephs, K. A., & Whitwell, J. L. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13256-0
Additional file 1 of A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation
Prins, S., Zhuparris, A., Hart, E. P., Doll, R.-J., & Groeneveld, G. J. (2021) · Figshare · doi:10.6084/m9.figshare.15000164
Analyse des troubles de la métamémoire de la phase pré-symptomatique de la maladie d'Alzheimer
Sambuchi, N. (2014) · doi:10.70675/d87ddd5fza102z443fz9d8bzccfc2cbeda57
Stade prodromal de la maladie d'Alzheimer : nature des déficits mnésiques et liens avec les biomarqueurs d'imagerie.
Tomadesso, C. (2018) · theses.fr (ABES) · doi:10.70675/7fad6418zff81z49c7z984dz63aa2e44d7fc
Vers une meilleure compréhension des facteurs psychoaffectifs (anxiété et dépression) dans le vieillissement normal et pathologique : liens avec la cognition et la neuroimagerie multimodale
Moulinet, I. (2020) · theses.fr (ABES) · doi:10.70675/45bad93dz6eeez45d1z8d85z5e83196b607c

Authors: Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., Vemuri, P., Petersen, R. C., & Jack, C. R.
Affiliations: Mayo Clinic (US)
ORCID: Mielke, Michelle M.
Wiste, Heather J.
Weigand, Stephen D.
Knopman, David S.
Lowe, Val J.
Geda, Yonas E.
Boeve, Bradley F.
Senjem, Matthew L.
Vemuri, Prashanthi
Petersen, Ronald C.
Jack, Clifford R.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2012-10-09
Volume: 79
Issue: 15
Pages: 1570-1577
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.0b013e31826e2696
PMC: PMC3475629
OpenAlex: W2004344916
Cited by: 163
References: 34
Citations by year: 2026: 1 · 2025: 6 · 2024: 6 · 2023: 12 · 2022: 12 · 2021: 13 · 2020: 12 · 2019: 17 · 2018: 11 · 2017: 15 · 2016: 10 · 2015: 17 · 2014: 14 · 2013: 15 · 2012: 2
FWCI: 10.97
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Neurology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Robert Wood Johnson Foundation
Alzheimer's Association
Eli Lilly and Company
Pfizer (R01 AG034676)
Baxter International
Mayo Foundation for Medical Education and Research (AG034676, AG016574, R01-AG034676)
European Commission
Eisai
National Institutes of Health (AG016574, AG034676, AG006786, AG011378)
National Institute on Aging (R01AG034676, AG-034676, U01AG037526, AG016574, AG011378, U01AG006786, AG-006786, R01AG011378, K01AG028573, RO1 AG011378, R01AG041851, R01 AG0113, P50AG016574)
National Institute of Mental Health (K01MH068351)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords: cerebral amyloidosis, Pittsburgh compound B PET, preclinical Alzheimer's disease, cognitively normal elderly, APOE ε4, age as predictor, subjective memory complaints, screening biomarkers, number needed to screen, Mayo Clinic Study of Aging
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Apolipoproteins E, Brain, Brain Mapping, Cognition, Female, Genotype, Humans, Male, Neuropsychological Tests, Radionuclide Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Indicators of amyloid burden in a population-based study of cognitively normal elderly

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks